Abstract
The purpose of evaluating prognostic factors in acute lymphoblastic leukemia is, first, to stratify patients into adverse- or good-risk groups, second, to determine different treatment options accordingly and, third, to evaluate their potential outcome. Prognostic factors are particularly relevant for disease-free survival and overall survival.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
We are sorry, but there is no personal subscription option available for your country.
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Gunz F, Baikie AG . Leukemia, 3rd edn. Nankodo, Ltd: Tokyo, 1974.
Hoelzer D, Thiel E, Loffler H, Bodenstein H, Plaumann L, Buchner T et al. Intensified therapy in acute lymphoblastic and acute undifferentiated leukemia in adults. Blood 1984; 64: 38–47.
Hoelzer D, Thiel E, Loffler H, Ganser A, Heimpel H, Buchner T et al. Risk groups in adult acute lymphoblastic leukemia. Haematol Blood Transfus 1987; 30: 104–110.
Gaynor J, Chapman D, Little C, McKenzie S, Miller W, Andreeff M et al. A cause-specific hazard rate analysis of prognostic factors among 199 adults with acute lymphoblastic leukemia: the Memorial Hospital experience since 1969. J Clin Oncol 1988; 6: 1014–1030.
Kantarjian HM, O’Brien S, Smith TL, Cortes J, Giles FJ, Beran M et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000; 18: 547–561.
Larson RA, Dodge RK, Burns CP, Lee EJ, Stone RM, Schulman P et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood 1995; 85: 2025–2037.
Bassan R, Hoelzer D . Modern therapy of acute lymphoblastic leukemia. J Clin Oncol 2011; 29: 532–543.
Gokbuget N, Hoelzer D, Arnold R, Bohme A, Bartram CR, Freund M et al. Treatment of adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL). Hematol Oncol Clin North Am 2000; 14: 1307–1325, ix.
Bassan R, Intermesoli T, Oldani E . Prognostic factors and risk adapted therapy. In: Gökbuget N, Bassan R, Dombret H et al. (eds) Recommendations of the European Working Group for Adult ALL, 1st edn. UNI-MED Verlag AG: Bremen, 2011.
Acknowledgements
NG has also received grant support from GlaxoSmithKline, Mundipharma, Genzyme Corporation, EUSA Pharma, Micromet Inc., Medac Inc. and the Jose Carreras Foundation.
This article was published as part of a supplement that was supported by Novartis, MSD Italia, Roche, Celgene, GlaxoSmithKline, Sanofi, Gilead, Adienne, Italfarmaco, Pierre Fabre Pharmaceuticals with an unrestricted educational contribution to AREO—Associazione Ricerche Emato-Oncologiche (Genoa) and AMS—Associazione Malattie del Sangue (Milan) for the purpose of advancing research in acute and chronic leukemia.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
NG has received consulting fees from Micromet Inc., Gilead, ERYtech Pharma and Mundipharma, and received lecture fees from Medac Inc., GlaxoSmithKline and Mundipharma. DH declares no conflict of interest.
Rights and permissions
About this article
Cite this article
Hoelzer, D., Gökbuget, N. Change in prognostic factors. Leukemia Suppl 1 (Suppl 2), S1–S2 (2012). https://doi.org/10.1038/leusup.2012.4
Published:
Issue Date:
DOI: https://doi.org/10.1038/leusup.2012.4
